90513-08-9Relevant academic research and scientific papers
TACHYKININ RECEPTOR ANTAGONISTS
-
Page 33, (2010/02/10)
The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.
Novel phenethanolamines
-
, (2008/06/13)
The tertiary amines of the formula STR1 wherein n represents a whole number of 1 to 5; X1 represents phenyl or phenyl mono-, di- or tri-substituted by R1, R2 and R3 ; X2 represents hydrogen, lower-alkyl, phenyl or phenyl mono-, di- or tri-substituted by R1, R2 and R3 ; Y represents hydrogen, lower-alkyl, hydroxymethyl, carboxy or lower-alkoxycarbonyl; Z represents a group of the formula STR2 R1, R2 and R3 represent hydrogen, halogen, hydroxy, benzyloxy, lower-alkyl, lower-alkoxy, hydroxymethyl, amino, acylamino, lower-alkoxybenzylamino, nitro, carbamoyl, trifluoromethyl or lower-alkylsulphonylmethyl; R4, R5 and R51 represent hydrogen, lower-alkyl, lower-alkoxy, lower alkanoyl, carboxy, cyano, hydroxy, hydroxy-lower-alkyl, acyloxy or a group --C(R6)=C(R7)COOR8, --SO2 R9, --C(O)R9 or --CH2 R10, with the proviso that R4 does not represent hydrogen when R5 represents hydroxy, lower-alkyl or lower-alkoxy; R6, R7 and R8 represent hydrogen or lower-alkyl; R9 represents amino, mono-lower-alkylamino or a group R; R represents di-lower-alkylamino, piperidino, morpholino, thiamorpholino, piperazino or the ether group of a lower aliphatic, cycloaliphatic or araliphatic alcohol or of a phenol; and R10 represents a group R and, where R1, R2 and R3 represent hydrogen, halogen, hydroxy, benzyloxy, lower-alkyl, lower-alkoxy, hydroxymethyl, amino, lower-alkoxybenzylamino or trifluoromethyl and simultaneously Y represents hydrogen, lower-alkyl or hydroxymethyl, R10 can also represent amino or mono-lower-alkylamino, have hypoglycaemic activity and reduce glycosuria. They are manufactured from corresponding primary or secondary amines.
